HistoGenetics, a New York-based biotech firm specialized in Human Leukocyte Antigen (HLA) typing services and Sequenced-Based Typing (SBT), has selected Illumina’s MiSeq sequencing system for use in its CLIA laboratory.

Illumina’s MiSeq is a low-cost personal sequencing system which provides individual researchers a platform with rapid turnaround time, accuracy, and improved ease of use.

It will enable applications such as amplicon sequencing, clone checking, small genome sequencing, ChIP-Seq, and RNA-Seq, all with a single, integrated instrument and at a fraction of current costs and time

Illumina will deploy multiple MiSeqs, which will complement HistoGenetics’ existing Sanger sequencing workflow to sequence HLA genes with high accuracy and speed.

Apart from their utility in tissue matching for transplants, HLA gene variations have known associations with a wide variety of autoimmune diseases, infectious diseases, and some cancers.

HistoGenetics chief executive officer and co-founder Dr. Nezih Cereb said, "By introducing the MiSeq, we will be able to provide gold-level high resolution typing to pre-transplant work-ups, as well as to registry donors, and improve the turnaround time for sample processing."

HistoGenetics, presently, provides two levels of resolution with HLA sequencing-based testing- high-level and registry-level resolution.

Llumina is a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function.